# Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor

Study · id `cardio:ct-nct01869309` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01869309](<https://clinicaltrials.gov/study/NCT01869309>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01869309

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

## Technical summary

Registry record NCT01869309. Randomized; no masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT01869309, source copy `cardio:ctgov-nct01869309-2014-11-21`, retrieved 2026-10-26)
- Start date: 2014-01 (registry gives no type) (ClinicalTrials.gov record NCT01869309, source copy `cardio:ctgov-nct01869309-2014-11-21`, retrieved 2026-10-26)
- Primary completion: 2015-12 (anticipated) (ClinicalTrials.gov record NCT01869309, source copy `cardio:ctgov-nct01869309-2014-11-21`, retrieved 2026-10-26)
- Completion: 2016-12 (anticipated) (ClinicalTrials.gov record NCT01869309, source copy `cardio:ctgov-nct01869309-2014-11-21`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01869309, source copy `cardio:ctgov-nct01869309-2014-11-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01869309-2014-11-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor
- Acronym: HEIGHTEN
- Condition: Coronary Artery Disease
- Intervention (Drug): Prasugrel
- Intervention (Drug): Ticagrelor
- Lead sponsor: LifeBridge Health
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Prasugrel (`cardio:prasugrel`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 3aaa2aa23f8ff49f9690f55d137d9ae65fbd651b5fe960413be1972b59256c0c
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
